Metformin clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Metformin Clinical Trials: Type 2 Diabetes and Beyond
Metformin has been a cornerstone in the treatment of type 2 diabetes since the 1950s, with robust evidence supporting its role as a first-line therapy due to its insulin-sensitizing and antihyperglycemic effects. Clinical trials have also explored its potential benefits in a wide range of other diseases, including cancer, neurodegenerative disorders, COVID-19, and psychiatric conditions, as well as its impact on aging and cardiovascular health .
Metformin in Cancer Clinical Trials
Numerous clinical trials have investigated metformin’s potential as an anti-cancer agent. While preclinical and epidemiological studies suggested possible antitumor effects, results from randomized clinical trials have been mixed. For example, in advanced pancreatic cancer, adding metformin to standard chemotherapy did not improve overall survival compared to placebo . Similarly, in metastatic breast cancer, metformin combined with chemotherapy did not significantly affect progression-free or overall survival in non-diabetic patients . However, in ovarian cancer, metformin was associated with a reduction in cancer stem-like cells and improved platinum sensitivity, with better-than-expected overall survival, supporting further investigation in larger trials . Systematic reviews of cancer trials highlight that while metformin’s antitumor efficacy in humans remains unproven, it may have promise in specific settings, such as improving metabolic factors, enhancing immune checkpoint blockade, and treating hormone-dependent cancers .
Metformin and Cardiovascular/Metabolic Effects in Type 1 Diabetes
In type 1 diabetes, metformin has been studied for its potential to reduce insulin requirements and improve cardiovascular outcomes. The REMOVAL trial found that while metformin did not significantly reduce the progression of atherosclerosis (as measured by carotid intima-media thickness), it did lower body weight and LDL cholesterol over three years. However, sustained improvements in glycemic control were not observed, and the trial did not support routine use of metformin for glycemic management in long-standing type 1 diabetes, though it may have a role in cardiovascular risk management .
Metformin in Neurodegenerative Disease and Cognitive Impairment
Metformin’s possible neuroprotective effects are being explored in ongoing clinical trials. The MET-FINGER trial is testing a combination of lifestyle intervention and metformin in older adults at risk for dementia, aiming to assess its impact on cognitive decline and related risk factors. This trial is notable for its precision-prevention approach and may inform future strategies for cognitive impairment prevention .
Metformin in COVID-19 Clinical Trials
Randomized, placebo-controlled clinical trials have evaluated metformin for acute COVID-19. A systematic review found that in two out of three trials, metformin improved clinical outcomes, such as reducing the need for oxygen and acute healthcare use. The evidence suggests a moderate certainty that metformin can help prevent healthcare use due to COVID-19, though more research is needed to clarify its role in treatment guidelines .
Metformin in Psychiatric Disorders
Metformin has also been tested in treatment-resistant bipolar depression, particularly in patients with insulin resistance. A randomized controlled trial found that patients whose insulin resistance was reversed with metformin experienced significant improvements in depression, anxiety, and overall functioning compared to those who remained insulin resistant. These findings suggest metformin may offer a novel approach for managing treatment-resistant bipolar depression, pending further replication .
Metformin and the Tumor Immune Microenvironment
In esophageal cancer, a phase II trial showed that low-dose metformin did not directly affect tumor cell proliferation or apoptosis but did reprogram the tumor immune microenvironment. Metformin increased infiltration of cytotoxic T and B lymphocytes and shifted macrophage populations toward a tumor-suppressive phenotype, suggesting it may serve as an immune response modifier in cancer therapy .
Metformin and Aging
Large-scale clinical trials such as MILES and TAME are underway to determine whether metformin can offset aging and extend lifespan. Early data suggest that metformin’s benefits may extend beyond glucose control, potentially improving vascular function and reducing inflammation, which could contribute to enhanced healthspan .
Conclusion
Clinical trials have established metformin as a safe and effective therapy for type 2 diabetes, with additional benefits in cardiovascular risk reduction and potential roles in cancer, neurodegenerative disease, COVID-19, and psychiatric disorders. While results in cancer and other non-diabetic conditions are mixed, ongoing and future trials will further clarify metformin’s broader therapeutic potential.
Sources and full results
Most relevant research papers on this topic